StemCell InstituteStemCell Institute Inc.7096東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP

StemCell Institute FY ending Mar 2020 results

StemCell Institute brought in ¥1.68B in revenue.

Out of every ¥100 of sales, about ¥23 is left as operating profit.

Where the money goes

For every ¥100 StemCell Institute sells, how much goes where, and how much is kept.

FY ending Mar 2020

Margin funnel (derived from reported values)Gross margin 67.6% → Operating margin 22.8% → Net margin 16.6%

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第25期(2023/04/01－2024/03/31)
ID S100TW622024-06-27Open
EDINET (FSA Japan)
有価証券報告書－第23期(令和3年4月1日－令和4年3月31日)
ID S100OD0Y2022-06-24Open
EDINET (FSA Japan)
有価証券報告書－第22期(令和2年4月1日－令和3年3月31日)
ID S100LVGX2021-06-30Open

Extracted from XBRL: 32 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.